In-depth guide

UPDATED FEB 2026

Part of the Transvaginal Mesh investigation

The short answer

C.R. Bard, now part of Becton Dickinson, settled over 3,000 mesh cases for more than $184 million.

Its Avaulta, Align, and Ajust mesh products were subjects of MDL 2187, the first major mesh MDL consolidated in West Virginia. Bard's per-case average was approximately $61,333.

People's Justice Research TeamUpdated February 23, 2026Fact-checked

Verified against court and regulatory records · No upfront fees · Your information is never sold

Free Case Review

Check your eligibility — free

Answer 2-3 quick questions to review your potential case.

Free · Confidential · About 2 minutes · A case specialist responds within 1 business day

Your answers are never sold or shared without your consent.

C.R. Bard was among the first transvaginal mesh defendants to face mass tort litigation. MDL 2187 — the Bard mesh MDL — was one of the six MDLs consolidated before Judge Goodwin in West Virginia. Bard's Avaulta Plus and Avaulta Solo (POP repair) and its Align and Ajust (SUI slings) caused documented erosion, pelvic pain, and sexual dysfunction in thousands of patients.

The Huskey v. Ethicon bellwether trial in West Virginia — despite being named for Ethicon — established important precedent affecting Bard and all mesh defendants on issues of failure to warn and design defect. Bard's global settlement of $184M+ resolved thousands of cases. Bard was acquired by Becton Dickinson in 2017, and BD remains responsible for legacy Bard mesh liabilities.

The full investigation

Part of the Transvaginal Mesh Investigation